JonesTrading Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $26
Portfolio Pulse from richadhand@benzinga.com
JonesTrading analyst Sean Kim initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces a price target of $26.
June 14, 2023 | 9:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals receives a Buy rating from JonesTrading analyst Sean Kim, with a price target of $26.
The Buy rating and price target of $26 announced by JonesTrading analyst Sean Kim for EyePoint Pharmaceuticals (EYPT) is likely to have a positive short-term impact on the stock price. Investors may see this as a sign of confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100